Claims
- 1. A compound of the formula (I):
- 2. A compound according to Claim 1, wherein:
R1 represents Z represents a carbon atom; R5 represents a hydroxy group; and R6 represents a hydrogen atom, a halogen atom or an alkyl group having from 1 to 6 carbon atoms.
- 3. A compound according to Claim 1, wherein R2 represents a hydrogen atom or a hydroxy group.
- 4. A compound according to Claim 1, wherein R3 represents a hydrogen atom or a methyl group.
- 5. A compound according to Claim 1, wherein A represents a substituted or unsubstituted cycloalkylene group having from 3 to 8 carbon atoms, or an heterocyclic group having from 4 to 8 atoms which consists of at least one carbon atom and from 1 to 2 nitrogen atoms wherein the substituent is at least one group selected from alkyl groups having from 1 to 6 carbon atoms or oxo groups.
- 6. A compound according to Claim 1, wherein A represents a cyclohexyl group, a cyclohexenyl group or a piperidinyl group.
- 7. A compound according to Claim 1, wherein A represents a cyclohexyl group.
- 8. A compound according to Claim 1, wherein X represents an alkylene group having from 1 to 3 carbon atoms, a heteroalkylene group having from 2 to 3 atoms, wherein one of said atoms is replaced by a sulfur atom or an oxygen atom
- 9. A compound according to Claim 1, wherein X represents an alkylene group having from 1 to 3 carbon atoms or a heteroalkylene group having from 2 to 3 atoms, wherein one of said atoms is replaced by a sulfur atom.
- 10. A compound of formula (Ia)
- 11. A compound according to Claim 1, wherein R4 represents a phenyl group, optionally substituted by at least one substituent selected from the group consisting of halogen atoms or alkyl groups having from 1 to 6 carbon atoms.
- 12. A compound according to Claim 1 selected from:
N-[cis-4-Hydroxy-4-(5-hydroxypyridin-2-yl)cyclohexyl]-3-phenylpropanamide hydrochloride; 3-(4-Chlorophenyl)-N-[cis-4-hydroxy-4-(5-hydroxypyridin-2-yl)cyclohexyl] propanamide; N-[cis-4-Hydroxy-4-(5-hydroxypyridin-2-yl)cyclohexyl]-N-methyl-3-phenylpropanamide; N-[trans-4-(5-Hydroxypyridin-2-yl)cyclohexyl]-3-phenylpropanamide hydrochloride; N-[trans-4-(5-Hydroxypyridin-2-yl)cyclohexyl]-N-methyl-3-phenylpropanamide hydrochloride; 3-(2,4-dichlorophenyl)-N-[cis-4-hydroxy-4-(5-hydroxypyridin-2-yl)cyclohexyl]propanamide; N-[cis-4-hydroxy-4-(5-hydroxypyridin-2-yl)cyclohexyl]-3-(4-methylphenyl)propanamide; 3-(2-fluorophenyl)-N-[cis-4-hydroxy-4-(5-hydroxypyridin-2-yl)cyclohexyl]propanamide; 3-(2-fluorophenyl)-N-[trans-4-(5-hydroxypyridin-2-yl)cyclohexyl]propanamide; 3-(4-fluorophenyl)-N-[trans-4-(5-hydroxypyridin-2-yl)cyclohexyl]propanamide; N-[trans-4-(5-hydroxypyridin-2-yl)cyclohexyl]-2-(phenylthio)acetamide; 3-(4-ethylphenyl)-N-[trans-4-(5-hydroxypyridin-2-yl)cyclohexyl]propanamide; 3-(2-chlorophenyl)-N-[trans-4-(5-hydroxypyridin-2-yl)cyclohexyl]propanamide; 3-(4-chlorophenyl)-N-[trans-4-(5-hydroxypyridin-2-yl)cyclohexyl]propanamide; 3-(4-methylphenyl)-N-[trans-4-(5-hydroxypyridin-2-yl)cyclohexyl]propanamide; 3-(2-fluorophenyl)-N-[cis-4-hydroxy-4-(5-hydroxypyridin-2-yl)cyclohexyl]-N-methylpropanamide; N-[4-(5-Hydroxypyridin-2-yl)cyclohex-3-en-1-yl]-3-phenylpropanamide; 2-fluorobenzyl [cis-4-hydroxy-4-(5-hydroxypyridin-2-yl)cyclohexyl]methylcarbamate; benzyl [cis-4-hydroxy-4-(5-hydroxypyridin-2-yl)cyclohexyl]methylcarbamate; 3-(2-fluorophenyl)-N-[1-(5-hydroxypyridin-2-yl)piperidin-4-yl]propanamide; and N-[1-(5-hydroxypyridin-2-yl)piperidin-4-yl]-3-(4-methylphenyl)propanamide; or a pharmaceutically acceptable salt thereof.
- 13. A pharmaceutical composition for the treatment of disease conditions caused by overactivation of NMDA NR2B receptor, in a mammalian subject, which comprises a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable ester of such compound, or a pharmaceutically acceptable salt thereof, and a suitable pharmaceutically acceptable carrier.
- 14. A method for the treatment of disease conditions caused by overactivation of NMDA NR2B receptor, in a mammalian subject, which comprises administering to said subject a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable ester of such compound, or a pharmaceutically acceptable salt thereof.
- 15. A pharmaceutical composition for the treatment of disease conditions caused by overactivation of NMDA NR2B receptor, in a mammalian subject, which comprises a therapeutically effective amount of a compound according to claim 10, or a pharmaceutically acceptable ester of such compound, or a pharmaceutically acceptable salt thereof, and a suitable pharmaceutically acceptable carrier.
- 16. A pharmaceutical composition for the treatment of disease conditions caused by overactivation of NMDA NR2B receptor, in a mammalian subject, which comprises a therapeutically effective amount of a compound according to claim 10, or a pharmaceutically acceptable ester of such compound, or a pharmaceutically acceptable salt thereof, and a suitable pharmaceutically acceptable carrier.
Parent Case Info
[0001] This application is a United States utility application, which claims the benefit of priority to U.S. provisional application Serial No. 60/434,361 filed Dec. 17, 2002.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60434361 |
Dec 2002 |
US |